Cytokinetics (CYTK)
(Delayed Data from NSDQ)
$48.30 USD
-0.68 (-1.39%)
Updated May 24, 2024 04:00 PM ET
After-Market: $48.28 -0.02 (-0.04%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Brokerage Reports
Cytokinetics, Incorporated [CYTK]
Reports for Purchase
Showing records 281 - 300 ( 305 total )
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
3Q11 Update: ?357 Partnership Talks Advance - Multi-Dose Phase 2 Data in ALS by YE11
Provider: RODMAN & RENSHAW, CO.
Analyst: NOCHOMOVITZ Y
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
3Q11 Update: ?357 Partnership Talks Advance - Multi-Dose Phase 2 Data in ALS by YE11
Provider: RODMAN & RENSHAW, CO.
Analyst: NOCHOMOVITZ Y
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Course Correction to Prioritize the Lead Assets
Provider: RODMAN & RENSHAW, CO.
Analyst: NOCHOMOVITZ Y
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Course Correction to Prioritize the Lead Assets
Provider: RODMAN & RENSHAW, CO.
Analyst: NOCHOMOVITZ Y
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
We are initiating coverage with a Market Outperform Rating and a 12-Month Target Price of $4.
Provider: RODMAN & RENSHAW, CO.
Analyst: NOCHOMOVITZ Y
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
We are initiating coverage with a Market Outperform Rating and a 12-Month Target Price of $4.
Provider: RODMAN & RENSHAW, CO.
Analyst: NOCHOMOVITZ Y
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Reports Q1:11 Earnings and Updates Clinical Developments
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of March 27
Provider: WEDBUSH SECURITIES INC.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Reports Q4:10 Earnings and Updates Clinical Developments
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
357 PIIa Results in ALS Setting - Promising Initial Progress.
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Q3:10 Earnings a Non-Event, Focus Remains on Full ALS Data in December
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Reports Q2:10 Earnings and Provides Update to CK-?357 and omecamtiv mecarbil Programs
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G